EMERAM Capital Partners

The three Managing Partners — Kai Köppen, Dr. Christian Näther and Dr. Kai Obring — lead investment decisions. They have been together since the firm’s founding in 2012. Each partner brings a track record from prior private equity roles in the German-speaking mid-market, though those earlier affiliations are not publicly detailed by EMERAM. The firm also draws on a senior advisor network chaired by Ralf Pütmann for sector-specific guidance.

EMERAM’s sourcing model leans heavily on the personal networks of its Managing Partners and the firm’s reputation within the German Mittelstand. Because the firm brands itself as a business development partner rather than a pure financial buyer, it can access founder-owned companies that might not run auction processes. The firm’s current portfolio of nine companies suggests it emphasizes concentrated, relationship-driven origination in digital transformation, health and energy transition verticals rather than broad intermediary-led sourcing.

EMERAM operates as an institutional asset manager, not a single-family office. The firm raises commingled funds and deploys them into mid-market buyout and growth situations. Its team members, including the Managing Partners, are employed by EMERAM BUSINESS PARTNERS GMBH, a service entity that advises the investment vehicles.

EMERAM invests directly into portfolio companies, nearly always taking control or significant minority positions that allow it to drive value-creation plans. The firm does not advertise a fund-of-funds program or LP commitments to other managers. Its strategy involves direct equity and buy-and-build development, often funding add-on acquisitions from its managed vehicles.

EMERAM targets growth-stage and mature mid-market companies that are ready to scale, not early-stage startups. Its deal toolkit includes succession-driven buyouts, management buy-ins, complex carve-outs and public-to-private transactions. Portfolio company sofatutor, for example, was a revenue-generating digital learning platform at the time of investment, reflecting EMERAM’s preference for proven business models with expansion potential.

EMERAM does not publish an exclusion list, but its stated sector focus — digital transformation, health & wellbeing, and energy transition — implies it sidesteps heavy industrials, speculative biotech and traditional financial services. The portfolio bears this out: it holds no automotive suppliers, chemicals manufacturers or retail banks. The firm’s DACH-only geography also suggests it avoids emerging-market exposures.

EMERAM does not publicly market a co-investment program for external limited partners. The firm’s model centers on acting as the lead or sole institutional investor in its portfolio companies, often partnering directly with founders. While LP co-investment rights might exist in its fund documents, none have been publicly exercised or reported.